View ValuationAmoy Diagnostics 将来の成長Future 基準チェック /16Amoy Diagnostics利益と収益がそれぞれ年間14.6%と12.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に18.5% 16%なると予測されています。主要情報14.6%収益成長率15.97%EPS成長率Biotechs 収益成長29.7%収益成長率12.7%将来の株主資本利益率18.47%アナリストカバレッジGood最終更新日01 Jun 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 30Amoy Diagnostics Co., Ltd. to Report First Half, 2026 Results on Jul 31, 2026Amoy Diagnostics Co., Ltd. announced that they will report first half, 2026 results on Jul 31, 2026Valuation Update With 7 Day Price Move • Jun 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥17.20, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 24x in the Biotechs industry in China. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥26.39 per share.Board Change • Jun 08Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Qiao Wu was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • May 20Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Director Qiao Wu was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 16Amoy Diagnostics Co., Ltd., Annual General Meeting, May 07, 2026Amoy Diagnostics Co., Ltd., Annual General Meeting, May 07, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian Chinaお知らせ • Mar 31Amoy Diagnostics Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026Amoy Diagnostics Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026お知らせ • Dec 31Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026Amoy Diagnostics Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026お知らせ • Oct 27Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an Equity Buyback for CNY 200 million worth of its shares.Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its common stock. The shares will be repurchased at no more than CNY 34.5 per share. The purpose of the program is to cancel the shares and reduce the share capital of the company. The company will used to cancel and reduce the company's registered capital. The authorization will be valid for 12 months.お知らせ • Sep 30Amoy Diagnostics Co., Ltd. to Report Q3, 2025 Results on Oct 25, 2025Amoy Diagnostics Co., Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025お知らせ • Jul 02Amoy Diagnostics Co., Ltd. to Report First Half, 2025 Results on Jul 29, 2025Amoy Diagnostics Co., Ltd. announced that they will report first half, 2025 results on Jul 29, 2025お知らせ • Apr 23Amoy Diagnostics Co., Ltd. Proposes Final Cash Dividend for the Year 2024Amoy Diagnostics Co., Ltd. proposed final cash dividend/10 shares (tax included) of CNY3.00000000 for the year 2024.お知らせ • Apr 22Amoy Diagnostics Co., Ltd., Annual General Meeting, May 14, 2025Amoy Diagnostics Co., Ltd., Annual General Meeting, May 14, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian Chinaお知らせ • Mar 31Amoy Diagnostics Co., Ltd. to Report Q1, 2025 Results on Apr 22, 2025Amoy Diagnostics Co., Ltd. announced that they will report Q1, 2025 results on Apr 22, 2025お知らせ • Dec 31Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2024 Results on Apr 22, 2025Amoy Diagnostics Co., Ltd. announced that they will report fiscal year 2024 results on Apr 22, 2025Reported Earnings • Oct 22Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.12 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.21 (up from CN¥0.12 in 3Q 2023). Revenue: CN¥305.0m (up 23% from 3Q 2023). Net income: CN¥83.4m (up 78% from 3Q 2023). Profit margin: 27% (up from 19% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 35%After last week's 35% share price gain to CN¥24.00, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 22x in the Biotechs industry in China. Total loss to shareholders of 45% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥23.05 per share.お知らせ • Sep 30Amoy Diagnostics Co., Ltd. to Report Q3, 2024 Results on Oct 22, 2024Amoy Diagnostics Co., Ltd. announced that they will report Q3, 2024 results on Oct 22, 2024Buy Or Sell Opportunity • Sep 18Now 20% undervaluedThe stock has been flat over the last 90 days, currently trading at CN¥18.30. The fair value is estimated to be CN¥22.93, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.3% over the last 3 years. Earnings per share has grown by 6.7%. Revenue is forecast to grow by 52% in 2 years. Earnings are forecast to grow by 55% in the next 2 years.お知らせ • Aug 16Amoy Diagnostics Co., Ltd. Elects Shen Zhe and Wu Qiao as Independent DirectorAmoy Diagnostics Co., Ltd. at the Extraordinary General Meeting of 2024 on 14 August 2024 approved election and nomination of independent directors, cumulative voting system applicable: Shen Zhe, independent director; Wu Qiao, independent director.Buy Or Sell Opportunity • Aug 09Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to CN¥18.42. The fair value is estimated to be CN¥23.04, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.3% over the last 3 years. Earnings per share has grown by 6.7%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 54% in the next 2 years.Reported Earnings • Jul 31Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.20 (up from CN¥0.18 in 2Q 2023). Revenue: CN¥309.7m (up 18% from 2Q 2023). Net income: CN¥79.7m (up 15% from 2Q 2023). Profit margin: 26% (in line with 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Jul 04Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 18% to CN¥17.51. The fair value is estimated to be CN¥22.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years. Earnings per share has grown by 8.3%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 52% in the next 2 years.お知らせ • Jun 29Amoy Diagnostics Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024Amoy Diagnostics Co., Ltd. announced that they will report first half, 2024 results on Jul 30, 2024Declared Dividend • May 27Dividend increased to CN¥0.15Dividend of CN¥0.15 is 7.1% higher than last year. Ex-date: 30th May 2024 Payment date: 30th May 2024 Dividend yield will be 0.8%, which is lower than the industry average of 1.6%. Sustainability & Growth Dividend is well covered by both earnings (22% earnings payout ratio) and cash flows (22% cash payout ratio). The dividend has increased by an average of 20% per year over the past 6 years and payments have been stable during that time. EPS is expected to grow by 75% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 25Amoy Diagnostics Co., Ltd. Announces Cash Dividend on A Shares for the Year 2023, Payable on 30 May 2024Amoy Diagnostics Co., Ltd. announced final cash dividend of CNY 1.50000000 per ten A shares (tax included) for the year 2023. Record date: 29 May 2024. Ex-date: 30 May 2024. Payment date: 30 May 2024.Reported Earnings • Apr 19Full year 2023 earnings released: EPS: CN¥0.66 (vs CN¥0.67 in FY 2022)Full year 2023 results: EPS: CN¥0.66 (down from CN¥0.67 in FY 2022). Revenue: CN¥1.04b (up 24% from FY 2022). Net income: CN¥261.5m (flat on FY 2022). Profit margin: 25% (down from 31% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.お知らせ • Apr 16Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian Chinaお知らせ • Apr 02Amoy Diagnostics Co., Ltd. (SZSE:300685) commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.Amoy Diagnostics Co., Ltd. (SZSE:300685) commences share repurchases on March 29, 2024, under the program mandated by shareholders in the Extraordinary General Meeting held on February 26, 2024. As per the mandate, the company is authorized to repurchase up to CNY 200 million worth of its common stock. The shares will be repurchased at no more than CNY 28 per share. The purpose of the program is to cancel the shares and reduce the share capital of the company. The company will use its own fund to fund the repurchase. The authorization will be valid for 12 months.お知らせ • Mar 30Amoy Diagnostics Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024Amoy Diagnostics Co., Ltd. announced that they will report Q1, 2024 results on Apr 23, 2024Buy Or Sell Opportunity • Feb 27Now 24% overvaluedOver the last 90 days, the stock has fallen 4.4% to CN¥21.30. The fair value is estimated to be CN¥17.21, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 57% in 2 years. Earnings are forecast to grow by 74% in the next 2 years.Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥19.68, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 62% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.23 per share.New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (22% net profit margin).お知らせ • Dec 29Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024Amoy Diagnostics Co., Ltd. announced that they will report fiscal year 2023 results on Apr 16, 2024お知らせ • Dec 13+ 1 more updateAmoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component IndexAmoy Diagnostics Co., Ltd. has been removed from Shenzhen Stock Exchange Component Index .New Risk • Oct 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 22% Last year net profit margin: 33% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (22% net profit margin).お知らせ • Sep 30Amoy Diagnostics Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023Amoy Diagnostics Co., Ltd. announced that they will report Q3, 2023 results on Oct 24, 2023Reported Earnings • Aug 01Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.087 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.18 (up from CN¥0.087 in 2Q 2022). Revenue: CN¥263.5m (up 41% from 2Q 2022). Net income: CN¥69.4m (up 95% from 2Q 2022). Profit margin: 26% (up from 19% in 2Q 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.お知らせ • Jul 01Amoy Diagnostics Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023Amoy Diagnostics Co., Ltd. announced that they will report first half, 2023 results on Aug 01, 2023お知らせ • May 17Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023Amoy Diagnostics Co., Ltd. announced 2022 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 1.40000000. Record date: 22 May 2023, Ex-date: 23 May 2023 and Payment date: 23 May 2023. 10% withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY0.14000000(10% x CNY1.40000000) Net cash dividend/10 shares after tax: CNY1.26000000(CNY1.40000000- CNY0.14000000).Reported Earnings • Apr 15Full year 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.61 in FY 2021)Full year 2022 results: EPS: CN¥0.67 (up from CN¥0.61 in FY 2021). Revenue: CN¥842.2m (down 8.2% from FY 2021). Net income: CN¥263.7m (up 10% from FY 2021). Profit margin: 31% (up from 26% in FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. 3 highly experienced directors. 4 independent directors (5 non-independent directors). Chairman Li-Mou Zheng is the most experienced director on the board, commencing their role in 2008. Non-Independent Director Xin Huang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Oct 25Third quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.16 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.35 (up from CN¥0.16 in 3Q 2021). Revenue: CN¥206.8m (down 16% from 3Q 2021). Net income: CN¥134.9m (up 107% from 3Q 2021). Profit margin: 65% (up from 26% in 3Q 2021). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥25.19, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 28x in the Biotechs industry in China. Total loss to shareholders of 8.7% over the past three years.Reported Earnings • Jul 31Second quarter 2022 earnings released: EPS: CN¥0.087 (vs CN¥0.17 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.087 (down from CN¥0.17 in 2Q 2021). Revenue: CN¥186.5m (down 17% from 2Q 2021). Net income: CN¥35.7m (down 48% from 2Q 2021). Profit margin: 19% (down from 30% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 44%, compared to a 36% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 19% per year.Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥34.93, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 33x in the Biotechs industry in China. Total returns to shareholders of 81% over the past three years.Board Change • Apr 27High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Deputy GM, Secretary of the Board of Directors & Non-Independent Director Jiemin Luo was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 13Full year 2021 earnings released: EPS: CN¥1.09 (vs CN¥0.82 in FY 2020)Full year 2021 results: EPS: CN¥1.09 (up from CN¥0.82 in FY 2020). Revenue: CN¥917.0m (up 26% from FY 2020). Net income: CN¥239.6m (up 33% from FY 2020). Profit margin: 26% (up from 25% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 25%, compared to a 49% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.Buying Opportunity • Apr 09Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 32%. The fair value is estimated to be CN¥60.16, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 71% in 2 years. Earnings is forecast to grow by 83% in the next 2 years.Reported Earnings • Mar 03Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CN¥1.05 (up from CN¥0.82 in FY 2020). Revenue: CN¥917.0m (up 26% from FY 2020). Net income: CN¥231.4m (up 28% from FY 2020). Profit margin: 25% (in line with FY 2020). Revenue missed analyst estimates by 3.5%. Over the next year, revenue is forecast to grow 36%, compared to a 43% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.21 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥246.8m (up 23% from 3Q 2020). Net income: CN¥65.2m (up 44% from 3Q 2020). Profit margin: 26% (up from 23% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jul 26Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.24 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥225.2m (up 17% from 2Q 2020). Net income: CN¥67.9m (up 24% from 2Q 2020). Profit margin: 30% (up from 28% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Apr 14Full year 2020 earnings released: EPS CN¥0.82 (vs CN¥0.63 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥728.4m (up 26% from FY 2019). Net income: CN¥180.3m (up 34% from FY 2019). Profit margin: 25% (up from 23% in FY 2019). The increase in margin was driven by higher revenue.Is New 90 Day High Low • Mar 10New 90-day low: CN¥67.96The company is down 13% from its price of CN¥77.73 on 10 December 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.12 per share.Is New 90 Day High Low • Feb 09New 90-day high: CN¥92.11The company is up 17% from its price of CN¥78.85 on 11 November 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥31.05 per share.Is New 90 Day High Low • Jan 22New 90-day high: CN¥87.26The company is up 10.0% from its price of CN¥79.00 on 23 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥27.80 per share.Is New 90 Day High Low • Dec 22New 90-day low: CN¥71.91The company is down 5.0% from its price of CN¥75.85 on 24 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥27.59 per share.Is New 90 Day High Low • Nov 27New 90-day low: CN¥72.29The company is down 18% from its price of CN¥88.26 on 28 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥24.49 per share.Reported Earnings • Oct 21Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥152.2m, up 9.0% from the prior year. Total revenue was CN¥649.9m over the last 12 months, up 20% from the prior year.業績と収益の成長予測XSEC:300685 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20281,672533N/A509312/31/20271,586487390444612/31/20261,40142532039863/31/20261,186356297369N/A12/31/20251,198361295365N/A9/30/20251,127290308377N/A6/30/20251,145300321373N/A3/31/20251,148281321365N/A12/31/20241,109255302342N/A9/30/20241,184315289324N/A6/30/20241,128279262295N/A3/31/20241,082268274312N/A12/31/20231,044261254299N/A9/30/2023951213222269N/A6/30/2023908301164222N/A3/31/2023831267108189N/A1/1/202384226471149N/A9/30/202287128775140N/A6/30/202291121881146N/A3/31/202294925088134N/A1/1/202291724094168N/A9/30/2021890231107196N/A6/30/2021844211125224N/A3/31/2021811198143235N/A12/31/2020728180163221N/A9/30/2020650153114167N/A6/30/2020595138126159N/A3/31/2020550129143170N/A12/31/2019578135N/A152N/A9/30/2019541140N/A153N/A6/30/2019502135N/A120N/A3/31/2019469134N/A104N/A12/31/2018439127N/A93N/A9/30/2018398122N/A108N/A6/30/2018384120N/A114N/A3/31/2018357103N/A96N/A12/31/201733094N/A92N/A9/30/201731582N/A70N/A6/30/201728878N/A49N/A3/31/201725867N/A40N/A12/31/201625367N/A32N/A6/30/201622042N/A24N/A3/31/201619832N/A22N/A12/31/201517721N/A19N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 300685の予測収益成長率 (年間14.6% ) は 貯蓄率 ( 2.4% ) を上回っています。収益対市場: 300685の収益 ( 14.6% ) CN市場 ( 25.9% ) よりも低い成長が予測されています。高成長収益: 300685の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 300685の収益 ( 12.7% ) CN市場 ( 15.9% ) よりも低い成長が予測されています。高い収益成長: 300685の収益 ( 12.7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 300685の 自己資本利益率 は、3年後には低くなると予測されています ( 18.5 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/21 02:27終値2026/07/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Amoy Diagnostics Co., Ltd. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関Pei ChengChina Galaxy Securities Co., Ltd.Jin ZhangChina International Capital Corporation LimitedZiyu HeChina International Capital Corporation Limited11 その他のアナリストを表示
お知らせ • Jun 30Amoy Diagnostics Co., Ltd. to Report First Half, 2026 Results on Jul 31, 2026Amoy Diagnostics Co., Ltd. announced that they will report first half, 2026 results on Jul 31, 2026
Valuation Update With 7 Day Price Move • Jun 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥17.20, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 24x in the Biotechs industry in China. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥26.39 per share.
Board Change • Jun 08Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Qiao Wu was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • May 20Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Independent Director Qiao Wu was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 16Amoy Diagnostics Co., Ltd., Annual General Meeting, May 07, 2026Amoy Diagnostics Co., Ltd., Annual General Meeting, May 07, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian China
お知らせ • Mar 31Amoy Diagnostics Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026Amoy Diagnostics Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026
お知らせ • Dec 31Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026Amoy Diagnostics Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026
お知らせ • Oct 27Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an Equity Buyback for CNY 200 million worth of its shares.Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its common stock. The shares will be repurchased at no more than CNY 34.5 per share. The purpose of the program is to cancel the shares and reduce the share capital of the company. The company will used to cancel and reduce the company's registered capital. The authorization will be valid for 12 months.
お知らせ • Sep 30Amoy Diagnostics Co., Ltd. to Report Q3, 2025 Results on Oct 25, 2025Amoy Diagnostics Co., Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025
お知らせ • Jul 02Amoy Diagnostics Co., Ltd. to Report First Half, 2025 Results on Jul 29, 2025Amoy Diagnostics Co., Ltd. announced that they will report first half, 2025 results on Jul 29, 2025
お知らせ • Apr 23Amoy Diagnostics Co., Ltd. Proposes Final Cash Dividend for the Year 2024Amoy Diagnostics Co., Ltd. proposed final cash dividend/10 shares (tax included) of CNY3.00000000 for the year 2024.
お知らせ • Apr 22Amoy Diagnostics Co., Ltd., Annual General Meeting, May 14, 2025Amoy Diagnostics Co., Ltd., Annual General Meeting, May 14, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian China
お知らせ • Mar 31Amoy Diagnostics Co., Ltd. to Report Q1, 2025 Results on Apr 22, 2025Amoy Diagnostics Co., Ltd. announced that they will report Q1, 2025 results on Apr 22, 2025
お知らせ • Dec 31Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2024 Results on Apr 22, 2025Amoy Diagnostics Co., Ltd. announced that they will report fiscal year 2024 results on Apr 22, 2025
Reported Earnings • Oct 22Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.12 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.21 (up from CN¥0.12 in 3Q 2023). Revenue: CN¥305.0m (up 23% from 3Q 2023). Net income: CN¥83.4m (up 78% from 3Q 2023). Profit margin: 27% (up from 19% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 35%After last week's 35% share price gain to CN¥24.00, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 22x in the Biotechs industry in China. Total loss to shareholders of 45% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥23.05 per share.
お知らせ • Sep 30Amoy Diagnostics Co., Ltd. to Report Q3, 2024 Results on Oct 22, 2024Amoy Diagnostics Co., Ltd. announced that they will report Q3, 2024 results on Oct 22, 2024
Buy Or Sell Opportunity • Sep 18Now 20% undervaluedThe stock has been flat over the last 90 days, currently trading at CN¥18.30. The fair value is estimated to be CN¥22.93, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.3% over the last 3 years. Earnings per share has grown by 6.7%. Revenue is forecast to grow by 52% in 2 years. Earnings are forecast to grow by 55% in the next 2 years.
お知らせ • Aug 16Amoy Diagnostics Co., Ltd. Elects Shen Zhe and Wu Qiao as Independent DirectorAmoy Diagnostics Co., Ltd. at the Extraordinary General Meeting of 2024 on 14 August 2024 approved election and nomination of independent directors, cumulative voting system applicable: Shen Zhe, independent director; Wu Qiao, independent director.
Buy Or Sell Opportunity • Aug 09Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to CN¥18.42. The fair value is estimated to be CN¥23.04, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.3% over the last 3 years. Earnings per share has grown by 6.7%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 54% in the next 2 years.
Reported Earnings • Jul 31Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.20 (up from CN¥0.18 in 2Q 2023). Revenue: CN¥309.7m (up 18% from 2Q 2023). Net income: CN¥79.7m (up 15% from 2Q 2023). Profit margin: 26% (in line with 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Jul 04Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 18% to CN¥17.51. The fair value is estimated to be CN¥22.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years. Earnings per share has grown by 8.3%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 52% in the next 2 years.
お知らせ • Jun 29Amoy Diagnostics Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024Amoy Diagnostics Co., Ltd. announced that they will report first half, 2024 results on Jul 30, 2024
Declared Dividend • May 27Dividend increased to CN¥0.15Dividend of CN¥0.15 is 7.1% higher than last year. Ex-date: 30th May 2024 Payment date: 30th May 2024 Dividend yield will be 0.8%, which is lower than the industry average of 1.6%. Sustainability & Growth Dividend is well covered by both earnings (22% earnings payout ratio) and cash flows (22% cash payout ratio). The dividend has increased by an average of 20% per year over the past 6 years and payments have been stable during that time. EPS is expected to grow by 75% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 25Amoy Diagnostics Co., Ltd. Announces Cash Dividend on A Shares for the Year 2023, Payable on 30 May 2024Amoy Diagnostics Co., Ltd. announced final cash dividend of CNY 1.50000000 per ten A shares (tax included) for the year 2023. Record date: 29 May 2024. Ex-date: 30 May 2024. Payment date: 30 May 2024.
Reported Earnings • Apr 19Full year 2023 earnings released: EPS: CN¥0.66 (vs CN¥0.67 in FY 2022)Full year 2023 results: EPS: CN¥0.66 (down from CN¥0.67 in FY 2022). Revenue: CN¥1.04b (up 24% from FY 2022). Net income: CN¥261.5m (flat on FY 2022). Profit margin: 25% (down from 31% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
お知らせ • Apr 16Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian China
お知らせ • Apr 02Amoy Diagnostics Co., Ltd. (SZSE:300685) commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.Amoy Diagnostics Co., Ltd. (SZSE:300685) commences share repurchases on March 29, 2024, under the program mandated by shareholders in the Extraordinary General Meeting held on February 26, 2024. As per the mandate, the company is authorized to repurchase up to CNY 200 million worth of its common stock. The shares will be repurchased at no more than CNY 28 per share. The purpose of the program is to cancel the shares and reduce the share capital of the company. The company will use its own fund to fund the repurchase. The authorization will be valid for 12 months.
お知らせ • Mar 30Amoy Diagnostics Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024Amoy Diagnostics Co., Ltd. announced that they will report Q1, 2024 results on Apr 23, 2024
Buy Or Sell Opportunity • Feb 27Now 24% overvaluedOver the last 90 days, the stock has fallen 4.4% to CN¥21.30. The fair value is estimated to be CN¥17.21, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 57% in 2 years. Earnings are forecast to grow by 74% in the next 2 years.
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥19.68, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 62% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.23 per share.
New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (22% net profit margin).
お知らせ • Dec 29Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024Amoy Diagnostics Co., Ltd. announced that they will report fiscal year 2023 results on Apr 16, 2024
お知らせ • Dec 13+ 1 more updateAmoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component IndexAmoy Diagnostics Co., Ltd. has been removed from Shenzhen Stock Exchange Component Index .
New Risk • Oct 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 22% Last year net profit margin: 33% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (22% net profit margin).
お知らせ • Sep 30Amoy Diagnostics Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023Amoy Diagnostics Co., Ltd. announced that they will report Q3, 2023 results on Oct 24, 2023
Reported Earnings • Aug 01Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.087 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.18 (up from CN¥0.087 in 2Q 2022). Revenue: CN¥263.5m (up 41% from 2Q 2022). Net income: CN¥69.4m (up 95% from 2Q 2022). Profit margin: 26% (up from 19% in 2Q 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
お知らせ • Jul 01Amoy Diagnostics Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023Amoy Diagnostics Co., Ltd. announced that they will report first half, 2023 results on Aug 01, 2023
お知らせ • May 17Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023Amoy Diagnostics Co., Ltd. announced 2022 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 1.40000000. Record date: 22 May 2023, Ex-date: 23 May 2023 and Payment date: 23 May 2023. 10% withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY0.14000000(10% x CNY1.40000000) Net cash dividend/10 shares after tax: CNY1.26000000(CNY1.40000000- CNY0.14000000).
Reported Earnings • Apr 15Full year 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.61 in FY 2021)Full year 2022 results: EPS: CN¥0.67 (up from CN¥0.61 in FY 2021). Revenue: CN¥842.2m (down 8.2% from FY 2021). Net income: CN¥263.7m (up 10% from FY 2021). Profit margin: 31% (up from 26% in FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. 3 highly experienced directors. 4 independent directors (5 non-independent directors). Chairman Li-Mou Zheng is the most experienced director on the board, commencing their role in 2008. Non-Independent Director Xin Huang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Oct 25Third quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.16 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.35 (up from CN¥0.16 in 3Q 2021). Revenue: CN¥206.8m (down 16% from 3Q 2021). Net income: CN¥134.9m (up 107% from 3Q 2021). Profit margin: 65% (up from 26% in 3Q 2021). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥25.19, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 28x in the Biotechs industry in China. Total loss to shareholders of 8.7% over the past three years.
Reported Earnings • Jul 31Second quarter 2022 earnings released: EPS: CN¥0.087 (vs CN¥0.17 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.087 (down from CN¥0.17 in 2Q 2021). Revenue: CN¥186.5m (down 17% from 2Q 2021). Net income: CN¥35.7m (down 48% from 2Q 2021). Profit margin: 19% (down from 30% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 44%, compared to a 36% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 19% per year.
Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥34.93, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 33x in the Biotechs industry in China. Total returns to shareholders of 81% over the past three years.
Board Change • Apr 27High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Deputy GM, Secretary of the Board of Directors & Non-Independent Director Jiemin Luo was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 13Full year 2021 earnings released: EPS: CN¥1.09 (vs CN¥0.82 in FY 2020)Full year 2021 results: EPS: CN¥1.09 (up from CN¥0.82 in FY 2020). Revenue: CN¥917.0m (up 26% from FY 2020). Net income: CN¥239.6m (up 33% from FY 2020). Profit margin: 26% (up from 25% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 25%, compared to a 49% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
Buying Opportunity • Apr 09Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 32%. The fair value is estimated to be CN¥60.16, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 71% in 2 years. Earnings is forecast to grow by 83% in the next 2 years.
Reported Earnings • Mar 03Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CN¥1.05 (up from CN¥0.82 in FY 2020). Revenue: CN¥917.0m (up 26% from FY 2020). Net income: CN¥231.4m (up 28% from FY 2020). Profit margin: 25% (in line with FY 2020). Revenue missed analyst estimates by 3.5%. Over the next year, revenue is forecast to grow 36%, compared to a 43% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Oct 28Third quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.21 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥246.8m (up 23% from 3Q 2020). Net income: CN¥65.2m (up 44% from 3Q 2020). Profit margin: 26% (up from 23% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jul 26Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.24 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥225.2m (up 17% from 2Q 2020). Net income: CN¥67.9m (up 24% from 2Q 2020). Profit margin: 30% (up from 28% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Apr 14Full year 2020 earnings released: EPS CN¥0.82 (vs CN¥0.63 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥728.4m (up 26% from FY 2019). Net income: CN¥180.3m (up 34% from FY 2019). Profit margin: 25% (up from 23% in FY 2019). The increase in margin was driven by higher revenue.
Is New 90 Day High Low • Mar 10New 90-day low: CN¥67.96The company is down 13% from its price of CN¥77.73 on 10 December 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.12 per share.
Is New 90 Day High Low • Feb 09New 90-day high: CN¥92.11The company is up 17% from its price of CN¥78.85 on 11 November 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥31.05 per share.
Is New 90 Day High Low • Jan 22New 90-day high: CN¥87.26The company is up 10.0% from its price of CN¥79.00 on 23 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥27.80 per share.
Is New 90 Day High Low • Dec 22New 90-day low: CN¥71.91The company is down 5.0% from its price of CN¥75.85 on 24 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥27.59 per share.
Is New 90 Day High Low • Nov 27New 90-day low: CN¥72.29The company is down 18% from its price of CN¥88.26 on 28 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥24.49 per share.
Reported Earnings • Oct 21Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥152.2m, up 9.0% from the prior year. Total revenue was CN¥649.9m over the last 12 months, up 20% from the prior year.